Results Published in the Journal Pharmacogenomics and Personalized Medicine Shows Proove Opioid Risk® Accurately Identifies Prescription Opioid Abuse Risk

IRVINE, Calif.April 19, 2017 /PRNewswire/ — As a Bronze Sponsor of the National Rx Drug Abuse and Heroin SummitProove® Biosciences, Inc. announces the first-ever peer-reviewed published clinical study analyzing genetics, environmental, and lifestyle factors to accurately predict prescription opioid abuse. In this study, researchers from the University of Southern California (USC), the Interventional Pain Institute in Baltimore, and Proove publish results showing that Proove Opioid Risk® accurately identifies patients at risk for Opioid Use Disorder (OUD).

This study, An Observational Study to Calculate Additive Risk to Opioids: A Validation Study of a Predictive Algorithm to Evaluate Opioid Use Disorder (O.S.C.A.R.), is published in the international peer-reviewed journal, Pharmacogenomics and Personalized Medicine (Impact Factor: 4.21). In this trial, researchers evaluated 908 pain patients using opioids, 258 subjects with OUD versus 650 controls. The O.S.C.A.R. study demonstrates that Proove Opioid Risk® is a precision medicine technology that successfully stratifies patient risk. Compared to “low” risk patients, “moderate” and “high” risk patients had increased odds of OUD (4.17-fold and 16.5-fold, respectively, with 95.7% sensitivity). .

“This study suggests that Proove Opioid Risk® is more accurate than questionnaires like the SOAPP-R in identifying patients who abuse opioids. It’s an excellent tool useful in guiding responsible pain treatment,” explains study author Dr. Maneesh Sharma, Medical Director of the Interventional Pain Institute in Baltimore.

Dr. Svetlana Kantorovich, Proove®’s R&D Director explains, “This is the first of many peer-reviewed publications over the next several months demonstrating the validity of Proove Opioid Risk®, building on the existing published evidence for each algorithm component.”

Study author, Dr. Steven Richeimer, Director of USC’s Pain Management Center and Associate Clinical Professor at the USC Keck School of Medicine, explains, “Precision medicine can potentially help physicians choose more effective treatments (similar to targeted cancer therapies), decrease iatrogenic addictions and overdoses by prescreening patients, and possibly even aid in the diagnosis of pain conditions.”

Proove Opioid Risk® is a proprietary precision medicine profile consisting of an algorithm which analyzes 17 variables (11 genetic and 6 lifestyle and behavioral factors) individually supported by over 30 peer-reviewed publications correlated with narcotic addiction and related behaviors. Balancing these factors (42% genetic and 58% non-genetic), Proove Opioid Risk® may assist in solving the prescription drug abuse epidemic.

https://www.prnewswire.com/news-releases/first-published-clinical-study-successfully-uses-precision-medicine-to-predict-prescription-opioid-abuse-300441884.html